HALO
Halozyme Therapeutics, Inc.NASDAQHealthcare$64.49-1.39%ClosedMarket Cap: $7.61B
As of 2026-04-06
Valuation
P/E (TTM)
24.02
PEG
—
P/B
155.46
P/S
5.45
EV/EBITDA
7.75
DCF Value
$131.15
FCF Yield
8.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
81.9%
Operating Margin
58.4%
Net Margin
22.7%
ROE
92.7%
ROA
32.9%
ROIC
23.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $451.8M | 77.4% | $254.4M | $-141.6M | $-1.20 | — |
| FY 2025 | $1.40B | 78.1% | $816.3M | $316.9M | $2.56 | — |
| Q3 2025 | $354.3M | 84.4% | $217.9M | $175.2M | $1.43 | — |
| Q2 2025 | $325.7M | 85.8% | $202.4M | $165.2M | $1.33 | — |
| Q1 2025 | $264.9M | 81.7% | $141.5M | $118.1M | $0.93 | — |
| Q4 2024 | $298.0M | 85.9% | $175.5M | $137.0M | $1.06 | — |
| FY 2024 | $1.02B | 84.3% | $551.5M | $444.1M | $3.43 | — |
| Q3 2024 | $290.1M | 83.0% | $163.2M | $137.0M | $1.05 | — |
| Q2 2024 | $231.4M | 75.2% | $117.2M | $93.2M | $0.72 | — |
| Q1 2024 | $195.9M | 76.5% | $95.5M | $76.8M | $0.60 | — |
| Q4 2023 | $230.0M | 77.3% | $101.0M | $85.4M | $0.65 | — |
| FY 2023 | $829.3M | 76.8% | $337.6M | $281.6M | $2.10 | — |